Mission Therapeutics

MISSION Therapeutics, founded in 2011 as a spin out from the University of Cambridge, focuses on the discovery and development of small molecules that target deubiquitinating enzymes, developed using DUB-Sphere, its proprietary DUB Drug Discovery Platform, to treat cancers and other diseases.In June 2020, the company its move to new purpose-built headquarters on the Babraham Research Campus, Cambridge, UK.In February 2016, the company raised GBP 60 million (US $85.77 million) including GBP 11.3 million (US $16.15 million) from Imperial Innovations Group with GBP 3.9 million (US $5.57 million) invested in the first tranche resulting in the Group's holding increased to 21.6% interest in the company,.In November 2013, the company received GBP 20 million (US $32.2 million) in a series B funding round, of which GBP $4.5 million (US $7.25 million) was funded by Imperial Innovations Group.In August 2011, the company received GBP 6 million (US $9.87 million) in funding